A new therapeutical approach in type 2 diabetes;Nuevos enfoques terapéuticos en la diabetes tipo 2

Medicina Clinica

Volumn 117, Issue 4, 2001, Pages 137-141

  Costa, B ^a  

^a NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ARTICLE; CARDIOVASCULAR RISK; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT INDICATION;

EID: 10944253242     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(01)72042-8     Document Type: Article

References (50)

1. Cost vs quality in different types of primary care settings
2. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Hearth Association
3. Asymptomatic hyperglycemia is associated with increased intimal plus medial thickness of the carotid artery
4. Intensive blood-glucose control with sulfonilureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
5. 1c level
6. A desktop guide for the management of type 2 diabetes mellitus
7. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
8. 1c does not reflect prandial plasma glucose excursions in type 2 diabetes
9. Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolereance
10. Risk of diabetes in the new diagnostic category of Impaired Fasting Glucose: A prospective analysis
11. Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: Assessment using nateglinide, a new insulin secretagogue
12. Evening insulin strategy
13. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy
14. Novel inhibitors of advanced glycation endproducts
15. Metabolic control in type 2 diabetes: The impact of prandial glucose
16. The post-prandial state and cardiovascular disease: Relevance to diabetes mellitus
17. A 6-year, randomised, controlled trial comparing sulphonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy (UKPDS 24)
18. Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort
19. The emerging role of post-prandial hyperglycemic spikes in the pathogenesis of diabetic complications
20. Glucose tolerance and mortality: Comparison of WHO and American Diabetes Association diagnostic criteria
21. Isolated postchallenge hyperglycaemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo Study
22. Glucose intolerance and 23-year risk of coronary heart disease and total mortality: The Honolulu Heart Program
23. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study
24. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study
25. Cytosolic triglycerides and oxidative stress in central obesity: The missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure?
26. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes
27. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients
28. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
29. Pathogenesis of NIDDM. A balanced overview
30. Pharmacological therapy for type 2 diabetes mellitus
31. Diabetes Mellitus tipo 2
32. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes
33. Repaglinide, a novel short-acting hypoglycemic agent for type 2 diabetes mellitus
34. Rosiglitazone
35. Alpha-glucosidase inhibitors
36. Acarbose in ambulatory treatment of non-insulin-dependent diabetes mellitus associated to imminent sulfonylurea failure. A randomised-multicentric trial in primary heath-care
37. The STOP-NIDDM Trial: An international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus
38. Stimulation of insulin release by non-sulphonylurea hypoglycaemic agents: The meglitinide family
39. Discontinuation after start of oral hypoglycemic agents (OHA) in first year
40. Metabolic effects of repaglinide, a new oral hypoglycemic agent in therapy-naïve type 2 diabetics
41. Repaglinide: A novel oral hypoglycemic agent in type 2 diabetes: A randomised, placebo-controlled, double-blind, fixed-dose study
42. Repaglinide versus glyburide: A one-year comparison trial
43. Pharmacology and clinical experience with repaglinide
44. Stimulation of insulin and somatostatin release by two meglitinide analogs
45. Reduced risk of delayed hypoglycemia with nateglinide compared to repaglinide
46. Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects
47. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia
48. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus
49. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
50. Clinical efficacy of new thiazolidinediones and glinides in the treatment of type 2 diabetes mellitus